Integration of models and experimentation to optimise the production of potential biotherapeutics

Drug Discovery Today

Volumn 18, Issue 23-24, 2013, Pages 1250-1255

  Royle, Kate E ^a   Jimenez Del Val, Ioscani ^a   Kontoravdi, Cleo ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; THERAPEUTIC PROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT;

BIOTECHNOLOGICAL PRODUCTION; CELL CULTURE; COMMERCIAL PHENOMENA; COMPUTATIONAL FLUID DYNAMICS; CRITICAL QUALITY ATTRIBUTE; DRUG DESIGN; DRUG QUALITY; DRUG RESEARCH; ENDOPLASMIC RETICULUM; EXPERIMENTATION; FOOD AND DRUG ADMINISTRATION; MODEL; NONHUMAN; PHYSICAL CHEMISTRY; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; QUALITY CONTROL; REVIEW; SCALE UP; UNFOLDED PROTEIN RESPONSE; ANIMAL; BIOLOGICAL THERAPY; CHEMICAL STRUCTURE; COMPUTER SIMULATION; DRUG DEVELOPMENT; HUMAN; PROCEDURES;

ANIMALS; BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; COMPUTER SIMULATION; DRUG DESIGN; DRUG DISCOVERY; HUMANS; MODELS, MOLECULAR; PROTEINS;

EID: 84889094657     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.07.002     Document Type: Review

References (41)

1. S. Kyriakopoulos, and C. Kontoravdi Analysis of the landscape of biologically-derived pharmaceuticals in Europe: Dominant production systems, molecule types on the rise and approval trends Eur. J. Pharm. Sci. 48 2013 428 441
2. EvaluatePharma (2013) World Preview 2018: Embracing the Patent Cliff (Available at: https://www.evaluategroup.com/wp2013).
3. S. Aggarwal What's fueling the biotech engine - 2011 to 2012 Nat. Biotechnol. 30 2012 1191 1197
4. K. Baxter An end to the myth: there is no drug development pipeline Sci. Transl. Med. 5 2013 1 4
5. M. Kessel The problems with today's pharmaceutical business - an outsider's view Nat. Biotechnol. 29 2011 27 33
6. S. Morgan The cost of drug development: a systematic review Health Policy 100 2011 4 17
7. S.M. Paul How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
8. ICH. (2009) Harmonized Tripartite Guideline on Pharmaceutical Development Q8(R2) (Available at: http://www.ich.org/fileadmin/Public-Web-Site/ICH- Products/Guidelines/Quality/Q8-R1/Step4/Q8-R2-Guideline.pdf, accessed July 2013).
9. M. Federici Analytical lessons learned from selected therapeutic protein drug comparability studies Biologicals 41 2013 131 147
10. A. Beck Characterization of therapeutic antibodies and related products Anal. Chem. 85 2013 715 736
11. M.C. Manning Stability of protein pharmaceuticals: an update Pharm. Res. 27 2010 544 575
12. S. Kumar Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions Pharm. Res. 28 2011 949 961
13. N.J. Agrawal Aggregation in protein-based biotherapeutics: computational studies and tools to identify aggregation-prone regions J. Pharm. Sci. 100 2011 5081 5095
14. G.G. Tartaglia, and M. Vendruscolo The Zyggregator method for predicting protein aggregation propensities Chem. Soc. Rev. 37 2008 1395 1401
15. N. Chennamsetty Design of therapeutic proteins with enhanced stability Proc. Natl. Acad. Sci. U. S. A. 106 2009 11937 11942
16. N. Chennamsetty Prediction of aggregation prone regions of therapeutic proteins J. Phys. Chem. B 114 2010 6614 6624
17. T.M. Lauer Developability index: a rapid in silico tool for the screening of antibody aggregation propensity J. Pharm. Sci. 101 2012 102 115
18. A.L. Demain, and P. Vaishnav Production of recombinant proteins by microbes and higher organisms Biotechnol. Adv. 27 2009 297 306
19. E. Angov Codon usage: nature's roadmap to expression and folding of proteins Biotechnol. J. 6 2011 650 659
20. J. Racle A computational framework for the design of optimal protein synthesis Biotechnol. Bioeng. 109 2012 2127 2133
21. M. Zhou Non-optimal codon usage affects expression, structure and function of clock protein FRQ Nature 495 2013 111 115
22. E.P. O'Brien Prediction of variable translation rate effects on cotranslational protein folding Nat. Commun. 3 2012 868
23. F.U. Hartl Molecular chaperones in protein folding and proteostasis Nature 475 2011 324 332
24. R.M. Vabulas Protein folding in the cytoplasm and the heat shock response Cold Spring Harb. Perspect. Biol. 2 2010 a004390
25. A. Sekhar Protein folding rates and thermodynamic stability are key determinants for interaction with the Hsp70 chaperone system Protein Sci. 21 2012 1489 1502
26. E.T. Powers FoldEco: a model for proteostasis in E. coli Cell. Rep. 1 2012 265 276
27. J. Carrera Empirical model and in vivo characterization of the bacterial response to synthetic gene expression show that ribosome allocation limits growth rate Biotechnol. J. 6 2011 773 783
28. I. Tabas, and D. Ron Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress Nat. Cell. Biol. 13 2011 184 190
29. D. Pincus BiP binding to the ER-stress sensor Ire1 tunes the homeostatic behavior of the unfolded protein response PLoS Biol. 8 2010 e1000415
30. K. Erguler A mathematical model of the unfolded protein stress response reveals the decision mechanism for recovery, adaptation and apoptosis BMC Syst. Biol. 7 2013 16
31. C.E. Doneanu Analysis of host-cell proteins in biotherapeutic proteins by comprehensive online two-dimensional liquid chromatography/mass spectrometry Mabs 4 2012 24 44
32. S. Mittermayr Multiplexed analytical glycomics: rapid and confident IgG N-glycan structural elucidation J. Proteome Res. 10 2011 3820 3829
33. P. Wechselberger Model-based analysis on the extractability of information from data in dynamic fed-batch experiments Biotechnol. Prog. 29 2013 285 296
34. P. Wechselberger Efficient feeding profile optimization for recombinant protein production using physiological information Bioprocess Biosyst. Eng. 35 2012 1637 1649
35. S. Craven Process model comparison and transferability across bioreactor scales and modes of operation for a mammalian cell bioprocess Biotechnol. Prog. 29 2013 186 196
36. A.S. Tait Host cell protein dynamics in the supernatant of a mAb producing CHO cell line Biotechnol. Bioeng. 109 2012 971 982
37. R.L. Fernandes Experimental methods and modeling techniques for description of cell population heterogeneity Biotechnol. Adv. 29 2011 575 599
38. R.P. Nolan, and K. Lee Dynamic model of CHO cell metabolism Metab. Eng. 13 2011 108 124
39. A. Behjousiar In situ monitoring of intracellular glucose and glutamine in CHO cell culture Plos One 7 2012 e34512
40. S. Selvarasu Combined in silico modeling and metabolomics analysis to characterize fed-batch CHO cell culture Biotechnol. Bioeng. 109 2012 1415 1429
41. I. Jimenez del Val A dynamic mathematical model for monoclonal antibody N-linked glycosylation and nucleotide sugar donor transport within a maturing Golgi apparatus Biotechnol. Prog. 27 2011 1730 1743